ARTICLE | Company News
Novan, Sato deal
January 20, 2017 7:59 PM UTC
Novan granted Sato exclusive rights to develop and commercialize SB204 and "related dosage forms" in Japan to treat acne. Novan will receive ¥1.3 billion ($11 million) up front and is eligible for up ...